Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

INTRODUCTION: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. METHOD: In this 6-month, phase 3, randomized, placebo-controlled trial, 611 patients with inadequate response to disease-modifying anti-rheumatic drugs (DMARD-IR) were randomized 4:4:1:1 to receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Kremer, Joel, Wallenstein, Gene, Kanik, Keith S., Connell, Carol, Gruben, David, Zwillich, Samuel H., Fleischmann, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632359/
https://www.ncbi.nlm.nih.gov/pubmed/26530039
http://dx.doi.org/10.1186/s13075-015-0825-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632359/
https://www.ncbi.nlm.nih.gov/pubmed/26530039
http://dx.doi.org/10.1186/s13075-015-0825-9

Ejemplares similares